Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans | Zendy

Fumiyuki Otsuka | Zendy; Marc Vorpahl | Zendy; Masataka Nakano | Zendy; Jason Foerst | Zendy; John Newell | Zendy; Kenichi Sakakura | Zendy; Robert Kutys | Zendy; Elena Ladich | Zendy; Aloke V. Finn | Zendy; Frank D. Kolodgie | Zendy; Renu Virmani | Zendy

Open Access

Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans

Author(s) -

Fumiyuki Otsuka,

Marc Vorpahl,

Masataka Nakano,

Jason Foerst,

John Newell,

Kenichi Sakakura,

Robert Kutys,

Elena Ladich,

Aloke V. Finn,

Frank D. Kolodgie,

Renu Virmani

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.001790

Subject(s) - medicine , stent , cardiology , restenosis , sirolimus , paclitaxel , thrombosis , urology , zotarolimus , fibrin , drug eluting stent , surgery , chemotherapy , immunology

Clinical trials have demonstrated that the second-generation cobalt-chromium everolimus-eluting stent (CoCr-EES) is superior to the first-generation paclitaxel-eluting stent (PES) and is noninferior or superior to the sirolimus-eluting stent (SES) in terms of safety and efficacy. It remains unclear whether vascular responses to CoCr-EES are different from those to SES and PES because the pathology of CoCr-EES has not been described in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research